|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forssell H, Pröh K, Wester M and Krona H:
Tumor size as measured at initial X-ray examination, not length of
bile duct stricture, predicts survival in patients with
unresectable pancreatic cancer. BMC Cancer. 12:4292012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirono S, Kawai M, Okada KI, Miyazawa M,
Shimizu A, Kitahata Y, Ueno M and Yamaue H: Treatment strategy for
borderline resectable pancreatic cancer with radiographic artery
involvement. Pancreas. 45:1438–1446. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharma VP, Anderson NT and Geusz ME:
Circadian properties of cancer stem cells in glioma cell cultures
and tumorspheres. Cancer Lett. 345:65–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hale JS, Sinyuk M, Rich JN and Lathia JD:
Decoding the cancer stem cell hypothesis in glioblastoma. CNS
Oncol. 2:319–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang Y, Ju B, Tian J, Liu F, Yu H, Xiao
H, Liu X, Liu W, Yao Z and Hao Q: Ovarian cancer stem cell-specific
gene expression profiling and targeted drug prescreening. Oncol
Rep. 31:1235–1248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gilbertson RJ and Graham TA: Cancer:
Resolving the stem-cell debate. Nature. 488:462–463. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosen JM and Jordan CT: The increasing
complexity of the cancer stem cell paradigm. Science.
324:1670–1673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stewart AK: Medicine. How thalidomide
works against cancer. Science. 343:256–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song L, Zhou X and Li X: Phase II trial of
granulocyte-macrophage colony-stimulating factor plus thalidomide
in older patients with castration-resistant prostate cancer. Mol
Clin Oncol. 3:865–868. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Milanovic D, Sticht C, Röhrich M, Maier P,
Grosu AL and Herskind C: Inhibition of 13-cis retinoic acid-induced
gene expression of reactive-resistance genes by thalidomide in
glioblastoma tumours in vivo. Oncotarget. 6:28938–28948. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruiz J, Case D, Enevold G, Rosdhal R,
Tatter SB, Ellis TL, McQuellon RP, McMullen KP, Stieber VW, Shaw EG
and Lesser GJ: A phase II trial of thalidomide and procarbazine in
adult patients with recurrent or progressive malignant gliomas. J
Neurooncol. 106:611–617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tunio MA, Hashmi A, Qayyum A, Naimatullah
N and Masood R: Low-dose thalidomide in patients with metastatic
renal cell carcinoma. J Pak Med Assoc. 62:876–879. 2012.PubMed/NCBI
|
|
17
|
Burris HA III, Jones SF, Shipley D, Meluch
AA, Greco FA, Barton JH, Yardley DA and Hainsworth JD: Phase II
study of capecitabine in combination with thalidomide in patients
with metastatic breast cancer. Cancer Invest. 28:408–412. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee HJ, You DD, Choi DW, Choi YS, Kim SJ,
Won YS and Moon HJ: Significance of CD133 as a cancer stem cell
markers focusing on the tumorigenicity of pancreatic cancer cell
lines. J Korean Surg Soc. 81:263–270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lyons JG, Lobo E, Martorana AM and
Myerscough MR: Clonal diversity in carcinomas: Its implications for
tumour progression and the contribution made to it by
epithelial-mesenchymal transitions. Clin Exp Metastasis.
25:665–677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wiseman DA, Werner SR and Crowell PL: Cell
cycle arrest by the isoprenoids perillyl alcohol, geraniol, and
farnesol is mediated by p21(Cip1) and p27(Kip1) in human pancreatic
adenocarcinoma cells. J Pharmacol Exp Ther. 320:1163–1170. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guillaumond F, Iovanna JL and Vasseur S:
Pancreatic tumor cell metabolism: Focus on glycolysis and its
connected metabolic pathways. Arch Biochem Biophys. 545:69–73.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Antoniou A, Hébrant A, Dom G, Dumont JE
and Maenhaut C: Cancer stem cells, a fuzzy evolving concept: A cell
population or a cell property? Cell Cycle. 12:3743–3748. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar R, Dholakia A and Rasheed Z: Stem
cell-directed therapies in pancreatic cancer. Curr Probl Cancer.
37:280–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding Q, Yoshimitsu M, Kuwahata T, Maeda K,
Hayashi T, Obara T, Miyazaki Y, Matsubara S, Natsugoe S and Takao
S: Establishment of a highly migratory subclone reveals that CD133
contributes to migration and invasion through
epithelial-mesenchymal transition in pancreatic cancer. Hum Cell.
25:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding Q, Miyazaki Y, Tsukasa K, Matsubara
S, Yoshimitsu M and Takao S: CD133 facilitates
epithelial-mesenchymal transition through interaction with the ERK
pathway in pancreatic cancer metastasis. Mol Cancer. 13:152014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weng CC, Kuo KK, Su HT, Hsiao PJ, Chen YW,
Wu DC, Hung WC and Cheng KH: Pancreatic tumor progression
associated with CD133 overexpression: Involvement of increased TERT
expression and epidermal growth factor receptor-dependent Akt
activation. Pancreas. 45:443–457. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan YL, Zheng M, Tang YL and Liang XH: A
new perspective of vasculogenic mimicry: EMT and cancer stem cells
(Review). Oncol Lett. 6:1174–1180. 2013.PubMed/NCBI
|
|
32
|
Hao J, Zhang Y, Deng M, Ye R, Zhao S, Wang
Y, Li J and Zhao Z: MicroRNA control of epithelial-mesenchymal
transition in cancer stem cells. Int J Cancer. 135:1019–1027. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai C, Yu JW, Wu JG, Lu RQ, Ni XC, Wang SL
and Jiang BJ: CD133 promotes the invasion and metastasis of gastric
cancer via epithelial-mesenchymal transition. Zhonghua Wei Chang
Wai Ke Za Zhi. 16:662–667. 2013.(In Chinese). PubMed/NCBI
|
|
34
|
Na DC, Lee JE, Yoo JE, Oh BK, Choi GH and
Park YN: Invasion and EMT-associated genes are up-regulated in B
viral hepatocellular carcinoma with high expression of CD133-human
and cell culture study. Exp Mol Pathol. 90:66–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
